TNFSF10 and central nervous system cancer: Indeed, KN-93 decreases proliferation in osteosarcoma [131], AML [98], T cell lymphoma [116], prostate cancer [114], endometrial cancer [94], glioma [120], colon cancer [99], breast cancer [110] and medullary thyroid cancer cells [112], induces apoptosis in prostate cancer [147,148], but not AML cells [98], and resensitises resistant melanoma cells to TRAIL-induced apoptosis [125] and resistant glioma cells to CH-11 [124,149] in vitro.